M&A Deal Summary

Alexion Pharmaceuticals Acquires Enobia Pharma

On December 28, 2011, Alexion Pharmaceuticals acquired healthcare services company Enobia Pharma for 1.1B USD

Acquisition Highlights
  • This is Alexion Pharmaceuticals’ 1st transaction in the Healthcare Services sector.
  • This is Alexion Pharmaceuticals’ 3rd largest (disclosed) transaction.
  • This is Alexion Pharmaceuticals’ 1st transaction in Canada.
  • This is Alexion Pharmaceuticals’ 1st transaction in Quebec.

M&A Deal Summary
Date 2011-12-28
Target Enobia Pharma
Sector Healthcare Services
Buyer(s) Alexion Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 1.1B USD
Advisor(s) BofA Securities (Financial)
Wilmer Cutler Pickering Hale and Dorr (Legal)

Target

Enobia Pharma

Montreal, Quebec, Canada
Enobia Pharma focuses on the development of therapies for patients with genetic metabolic bone disorders. Enobia's lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. Enobia is based in Montreal, Quebec.

Search 199,968 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Alexion Pharmaceuticals

Boston, Connecticut, United States
Category Company
Founded 1992
Sector Life Science
Employees3,082
Revenue 6.1B USD (2020)
DESCRIPTION

Alexion Pharmaceuticals is a biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope. Alexion Pharmaceuticals was formed in 1992 and is based in New Haven, Connecticut.

DEAL STATS #
Overall 3 of 9
Sector (Healthcare Services) 1 of 1
Type (Add-on Acquisition) 3 of 9
State (Quebec) 1 of 1
Country (Canada) 1 of 1
Year (2011) 2 of 2
Size (of disclosed) 3 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-01-31 Taligen Therapeutics

Cambridge, Massachusetts, United States

Taligen is a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease.

Buy $111M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-05-06 Synageva BioPharma

Lexington, Massachusetts, United States

Synageva BioPharma Corp. is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The company's pipeline consists of protein therapeutic programs for rare diseases with unmet medical need which are currently at various stages of development.

Buy $8.4B
Mergr

Product

Company

Legal